HERE IS A SECOND CHART
Some of the same data from Chart 1 in the above article has been consolidated in Chart 2 below. Sweden and India were added to make a totally different comparison. India is there because of an independent analysis titled "Early treatment with hydroxychloroquine: a country-based analysis." It identified India as an early and widespread user of HCQ. The referenced analysis reviewed "[m]any countries that adopted or declined early treatment with HCQ, effectively forming a large trial with 1.8 billion people in the treatment group and 663 million in the control group." Their analysis found that the countries using HCQ early and extensively had 70.7% lower total deaths. Although India is a relatively poor country and has a less robust medical infrastructure, and its lockdowns and mask mandates were minimal and likely undercounted COVID deaths, its low death trend was consistent with other heavily HCQ-using countries. Additionally, India's over–1 billion population provided a huge sample size.
Note: HCQ and other corticosteroids do not kill the virus. They work by preventing the body's autoimmune system from overreacting (AKA a cytokine storm) and attacking the body instead of the virus. Susceptibility to this type overreaction increases with age. It is the resulting inflammation that is the primary cause of COVID deaths. When the cytokine storm reaction is controlled, antibodies that kill the virus are produced normally. To be effective, HCQ must be administered early, well before severe symptoms develop.
Also included in Chart 2 is the trend for Sweden. Sweden is added because it broke with conventional wisdom and mostly avoided lockdowns and mask mandates. Its initial death counts were as bad as the other countries. However, only Sweden did not experience the second wave, and its average daily death rate as of October 28 reached zero!